Masaki Ri

28PUBLICATIONS
49CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Nov 27, 2025
Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma.

Toru Ebina, Masaki Ri, Yoshiaki Marumo

|May 09, 2025
Immunosuppressive Effects of Multiple Myeloma-Derived Extracellular Vesicles Through T Cell Exhaustion.

Shinya Hagiwara, Masaki Ri, Toru Ebina

|May 07, 2025
Prevalence of CCR7-Positive CD8 T Cells as a Prognostic Factor in B-Cell Maturation Antigen -Targeted Chimeric Antigen Receptor T Cell Therapy.

Yoshiaki Marumo, Masaki Ri, Toru Ebina

|Apr 23, 2025
Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.

Tomotaka Suzuki, Keiichiro Fujii, Naohiro Matsunaga

|Jul 20, 2024
Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone.

Takuto Tachita, Masaki Ri, Sho Aoki

|Mar 01, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.

Yasunori Kogure, Hiroshi Handa, Yuta Ito

Pageof 5

Frequent Collaborators

14 joint publications

Shinsuke Iida

4 joint publications

Shigeru Kusumoto

4 joint publications

Tomotaka Suzuki

3 joint publications

Tadao Ishida